Literature DB >> 23807484

Atorvastatin counteracts aberrant soft tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6⁻/⁻).

Haitao Guo1, Qiaoli Li, David W Chou, Jouni Uitto.   

Abstract

UNLABELLED: Pseudoxanthoma elasticum (PXE), a multisystem heritable disorder with aberrant mineralization of arterial blood vessels, is caused by mutations in the ABCC6 gene. Previous studies have suggested that carriers of the ABCC6 mutations, particularly of p.R1141X, are at increased risk for coronary artery disease. In this study, we used Abcc6 (tm1Jfk) knock-out mice to determine the serum lipid profiles and examine the effects of atorvastatin on the aberrant mineralization in this model of PXE. First, serum lipid profiles at 12 weeks of age, after overnight fasting, revealed a statistically significant increase in total cholesterol and triglyceride levels in Abcc6 (tm1Jfk) mice compared to their wild-type littermates. Placing these mice at 4 weeks of age for 20 weeks on atorvastatin, either 0.01 % or 0.04 % of the diet (low statin and high statin groups, respectively), reduced the total triglyceride and cholesterol levels, which was accompanied with significantly reduced mineralization of the dermal sheath of vibrissae, a biomarker of the aberrant mineralization process in these mice. However, if the mice were placed on atorvastatin for 12 weeks at 12 weeks of age, at which time point significant mineralization had already taken place, no difference in the amount of mineralization was noted. These observations suggest that statins, particularly atorvastatin, can prevent, but not reverse, aberrant mineralization in this mouse model of PXE. For a clinical perspective, a survey of 1,747 patients with PXE was conducted regarding their present or past use of statins. The results indicated that about one third of all PXE patients are currently or have previously been on cholesterol-lowering drugs. Thus, a sizable number of patients with PXE could be subject to modulation of their mineralization processes by concomitant statin treatment. KEY MESSAGE: The Abcc6 (-/-) mice serve as a model system for PXE, an ectopic mineralization disorder Abcc6 (-/-) mice were shown to have elevated serum cholesterol and triglyceride levels Feeding of the Abcc6 (-/-) mice with atorvastatin prevented connective tissue mineralization A third of patients with PXE was found to be on cholesterol-lowering therapy Atorvastatin may potentially be beneficial for patients with PXE.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23807484      PMCID: PMC3783622          DOI: 10.1007/s00109-013-1066-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  24 in total

1.  Pseudoxanthoma elasticum.

Authors:  K H Neldner
Journal:  Clin Dermatol       Date:  1988 Jan-Mar       Impact factor: 3.541

2.  Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice.

Authors:  Sweder W E van de Poll; Dianne J M Delsing; J Wouter Jukema; Hans M G Princen; Louis M Havekes; Gerwin J Puppels; Arnoud van der Laarse
Journal:  J Mol Cell Cardiol       Date:  2003-01       Impact factor: 5.000

3.  Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues.

Authors:  John F Klement; Yasushi Matsuzaki; Qiu-Jie Jiang; Joseph Terlizzi; Hae Young Choi; Norihiro Fujimoto; Kehua Li; Leena Pulkkinen; David E Birk; John P Sundberg; Jouni Uitto
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

4.  Patients with premature coronary artery disease who carry the ABCC6 R1141X mutation have no Pseudoxanthoma Elasticum phenotype.

Authors:  Jurgen J Wegman; Xiaofeng Hu; Hendra Tan; Arthur A B Bergen; Mieke D Trip; John J P Kastelein; Yvo M Smulders
Journal:  Int J Cardiol       Date:  2005-04-28       Impact factor: 4.164

5.  Effect of statins on bone mineral density and bone histomorphometry in rodents.

Authors:  F J Maritz; M M Conradie; P A Hulley; R Gopal; S Hough
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

6.  Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice.

Authors:  S W van De Poll; T J Römer; O L Volger; D J Delsing; T C Bakker Schut; H M Princen; L M Havekes; J W Jukema; A van Der Laarse; G J Puppels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

7.  Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum.

Authors:  Theo G M F Gorgels; Xiaofeng Hu; George L Scheffer; Allard C van der Wal; Johan Toonstra; Paulus T V M de Jong; Toin H van Kuppevelt; Christiaan N Levelt; Anneke de Wolf; Willem J P Loves; Rik J Scheper; Ron Peek; Arthur A B Bergen
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

8.  Synthesis and characterization of a fluvastatin-releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration.

Authors:  Danielle S W Benoit; Charles R Nuttelman; Stuart D Collins; Kristi S Anseth
Journal:  Biomaterials       Date:  2006-07-24       Impact factor: 12.479

9.  Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells.

Authors:  Toyonobu Maeda; Ayako Matsunuma; Izuru Kurahashi; Toru Yanagawa; Hiroshi Yoshida; Noboru Horiuchi
Journal:  J Cell Biochem       Date:  2004-06-01       Impact factor: 4.429

Review 10.  Statins and bone metabolism.

Authors:  N Horiuchi; T Maeda
Journal:  Oral Dis       Date:  2006-03       Impact factor: 3.511

View more
  16 in total

1.  Pseudoxanthoma elasticum and statin prophylaxis.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2013-10       Impact factor: 4.599

2.  Atherogenic Diet Accelerates Ectopic Mineralization in a Mouse Model of Pseudoxanthoma Elasticum.

Authors:  Jing-Yi Zhao; Joshua Kingman; Ida Joely Jacobs; Jouni Uitto; Yi Cao; Qiao-Li Li
Journal:  Int J Dermatol Venereol       Date:  2020-05-14

3.  PSEUDOXANTHOMA ELASTICUM: DIAGNOSTIC FEATURES, CLASSIFICATION, AND TREATMENT OPTIONS.

Authors:  Jouni Uitto; Qiujie Jiang; András Váradi; Lionel G Bercovitch; Sharon F Terry
Journal:  Expert Opin Orphan Drugs       Date:  2014-06-01       Impact factor: 0.694

4.  Relationships between Plasma Pyrophosphate, Vascular Calcification and Clinical Severity in Patients Affected by Pseudoxanthoma Elasticum.

Authors:  Georges Leftheriotis; Nastassia Navasiolava; Laetitia Clotaire; Christophe Duranton; Olivier Le Saux; Saïd Bendahhou; Audrey Laurain; Isabelle Rubera; Ludovic Martin
Journal:  J Clin Med       Date:  2022-05-05       Impact factor: 4.241

Review 5.  The ABCC6 Transporter as a Paradigm for Networking from an Orphan Disease to Complex Disorders.

Authors:  Eva Y G De Vilder; Mohammad Jakir Hosen; Olivier M Vanakker
Journal:  Biomed Res Int       Date:  2015-08-18       Impact factor: 3.411

6.  ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?

Authors:  Patricia Kuzaj; Joachim Kuhn; Mareike Dabisch-Ruthe; Isabel Faust; Christian Götting; Cornelius Knabbe; Doris Hendig
Journal:  Lipids Health Dis       Date:  2014-07-27       Impact factor: 3.876

7.  Pseudoxanthoma elasticum.

Authors:  Bruna Morassi Sasso; Maria Letícia Cintra; Elemir Macedo de Souza
Journal:  Autops Case Rep       Date:  2017-12-08

Review 8.  Pseudoxanthoma elasticum.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2017-05-10       Impact factor: 4.123

9.  Genetic deletion of Abcc6 disturbs cholesterol homeostasis in mice.

Authors:  Bettina Ibold; Janina Tiemann; Isabel Faust; Uta Ceglarek; Julia Dittrich; Theo G M F Gorgels; Arthur A B Bergen; Olivier Vanakker; Matthias Van Gils; Cornelius Knabbe; Doris Hendig
Journal:  Sci Rep       Date:  2021-01-22       Impact factor: 4.379

10.  Cellular and Molecular Biomarkers Indicate Premature Aging in Pseudoxanthoma Elasticum Patients.

Authors:  Janina Tiemann; Thomas Wagner; Olivier M Vanakker; Matthias van Gils; José-Luis Bueno Cabrera; Bettina Ibold; Isabel Faust; Cornelius Knabbe; Doris Hendig
Journal:  Aging Dis       Date:  2020-05-09       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.